Relief Therapeutics Holding AG (RLF.SW)
CHF 4.1
(-6.82%)
CHF 4.1
(-6.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -98.18 Million CHF | -93.31% |
| 2022 | -50.79 Million CHF | -46.35% |
| 2021 | -34.7 Million CHF | -343.34% |
| 2020 | -7.82 Million CHF | -4.93% |
| 2019 | -7.46 Million CHF | -1611.01% |
| 2018 | -436 Thousand CHF | 84.9% |
| 2017 | -2.88 Million CHF | 82.85% |
| 2016 | -16.83 Million CHF | -83.89% |
| 2015 | -9.15 Million CHF | 25.46% |
| 2014 | -12.28 Million CHF | -0.89% |
| 2013 | -12.17 Million CHF | -87.69% |
| 2012 | -6.48 Million CHF | 89.04% |
| 2011 | -59.16 Million CHF | -205.03% |
| 2010 | -19.39 Million CHF | -58.81% |
| 2009 | -12.21 Million CHF | -29.92% |
| 2008 | -9.4 Million CHF | -369.97% |
| 2007 | -2 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.55 Million CHF | 0.0% |
| 2023 Q2 | -56.49 Million CHF | 0.0% |
| 2023 FY | -98.18 Million CHF | -93.31% |
| 2023 Q4 | -41.68 Million CHF | 0.0% |
| 2022 FY | -50.79 Million CHF | -46.35% |
| 2022 Q2 | -26.5 Million CHF | 0.0% |
| 2022 Q4 | -24.29 Million CHF | 0.0% |
| 2021 Q2 | -14.67 Million CHF | 0.0% |
| 2021 Q4 | -20.02 Million CHF | 0.0% |
| 2021 FY | -34.7 Million CHF | -343.34% |
| 2020 Q2 | 8.25 Million CHF | 0.0% |
| 2020 FY | -7.82 Million CHF | -4.93% |
| 2020 Q4 | -16.07 Million CHF | 0.0% |
| 2019 Q2 | -556 Thousand CHF | 0.0% |
| 2019 FY | -7.46 Million CHF | -1611.01% |
| 2019 Q4 | -6.9 Million CHF | 0.0% |
| 2018 Q2 | -365 Thousand CHF | 0.0% |
| 2018 Q4 | -71 Thousand CHF | 0.0% |
| 2018 FY | -436 Thousand CHF | 84.9% |
| 2017 FY | -2.88 Million CHF | 82.85% |
| 2017 Q4 | -1.81 Million CHF | 0.0% |
| 2017 Q2 | -1.06 Million CHF | 0.0% |
| 2016 Q1 | -4.2 Million CHF | 0.0% |
| 2016 FY | -16.83 Million CHF | -83.89% |
| 2016 Q2 | -273 Thousand CHF | 93.51% |
| 2016 Q4 | -16.56 Million CHF | 0.0% |
| 2015 Q3 | -1.06 Million CHF | 0.0% |
| 2015 FY | -9.15 Million CHF | 25.46% |
| 2015 Q1 | -1.06 Million CHF | 0.0% |
| 2015 Q4 | -4.2 Million CHF | -293.37% |
| 2015 Q2 | -1.06 Million CHF | 0.0% |
| 2014 Q4 | -1.06 Million CHF | 65.16% |
| 2014 FY | -12.28 Million CHF | -0.89% |
| 2014 Q3 | -3.07 Million CHF | 0.0% |
| 2014 Q2 | -3.07 Million CHF | 0.0% |
| 2014 Q1 | -3.07 Million CHF | 0.0% |
| 2013 Q4 | -3.07 Million CHF | -0.52% |
| 2013 Q3 | -3.05 Million CHF | 0.0% |
| 2013 Q2 | -3.05 Million CHF | 0.0% |
| 2013 Q1 | -3.05 Million CHF | 0.0% |
| 2013 FY | -12.17 Million CHF | -87.69% |
| 2012 FY | -6.48 Million CHF | 89.04% |
| 2012 Q4 | -3.05 Million CHF | -88.42% |
| 2012 Q2 | -1.62 Million CHF | 0.0% |
| 2012 Q1 | -1.62 Million CHF | 0.0% |
| 2012 Q3 | -1.62 Million CHF | 0.0% |
| 2011 Q2 | -14.87 Million CHF | 0.0% |
| 2011 Q4 | -1.62 Million CHF | 89.1% |
| 2011 FY | -59.16 Million CHF | -205.03% |
| 2011 Q3 | -14.87 Million CHF | 0.0% |
| 2011 Q1 | -14.87 Million CHF | 0.0% |
| 2010 Q1 | -4.94 Million CHF | 0.0% |
| 2010 Q4 | -14.87 Million CHF | -200.52% |
| 2010 Q3 | -4.94 Million CHF | 0.0% |
| 2010 Q2 | -4.94 Million CHF | 0.0% |
| 2010 FY | -19.39 Million CHF | -58.81% |
| 2009 Q2 | -3.05 Million CHF | 0.0% |
| 2009 Q3 | -3.05 Million CHF | 0.0% |
| 2009 Q4 | -4.94 Million CHF | -62.1% |
| 2009 FY | -12.21 Million CHF | -29.92% |
| 2009 Q1 | -3.05 Million CHF | 0.0% |
| 2008 Q4 | -3.05 Million CHF | -19.97% |
| 2008 Q2 | -2.54 Million CHF | 0.0% |
| 2008 Q1 | -2.54 Million CHF | 0.0% |
| 2008 FY | -9.4 Million CHF | -369.97% |
| 2008 Q3 | -2.54 Million CHF | 0.0% |
| 2007 FY | -2 Million CHF | 0.0% |
| 2007 Q3 | -500.07 Thousand CHF | 0.0% |
| 2007 Q2 | -500.07 Thousand CHF | 0.0% |
| 2007 Q1 | -500.07 Thousand CHF | 0.0% |
| 2007 Q4 | -2.54 Million CHF | -408.96% |
| 2006 Q4 | -500.07 Thousand CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.55 Million CHF | -830.077% |
| BB Biotech AG | -206.6 Million CHF | 52.479% |
| Basilea Pharmaceutica AG | 10.45 Million CHF | 1039.441% |
| Evolva Holding SA | -105.22 Million CHF | 6.698% |
| Idorsia Ltd | -297.92 Million CHF | 67.045% |
| Kuros Biosciences AG | -13.72 Million CHF | -615.24% |
| Molecular Partners AG | -61.98 Million CHF | -58.397% |
| Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 279.221% |